MedTrace Logo

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

NCT00161954 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-05-21

No results posted yet for this study

Summary

The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.

Conditions

  • Encephalitis, Tick-borne

Interventions

BIOLOGICAL

Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

Sponsors & Collaborators

Principal Investigators

  • Baxter BioScience Investigator · Baxter BioScience

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Completion
2004-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161954 on ClinicalTrials.gov